DNLVX
Price
$19.46
Change
+$0.12 (+0.62%)
Updated
Apr 2 closing price
Net Assets
174.13M
VIVAX
Price
$67.64
Change
+$0.38 (+0.56%)
Updated
Apr 2 closing price
Net Assets
195.24B
Ad is loading...

DNLVX vs VIVAX

Header iconDNLVX vs VIVAX Comparison
Open Charts DNLVX vs VIVAXBanner chart's image
Dunham Large Cap Value N
Price$19.46
Change+$0.12 (+0.62%)
VolumeN/A
Net Assets174.13M
Vanguard Value Index I
Price$67.64
Change+$0.38 (+0.56%)
VolumeN/A
Net Assets195.24B
DNLVX vs VIVAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DNLVX vs. VIVAX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLVX is a Buy and VIVAX is a StrongBuy.

Ad is loading...
FUNDAMENTALS
Fundamentals
VIVAX has more cash in the bank: 195B vs. DNLVX (174M). VIVAX pays higher dividends than DNLVX: VIVAX (2.14) vs DNLVX (0.80). DNLVX was incepted earlier than VIVAX: DNLVX (20 years) vs VIVAX (32 years). DNLVX (1.04) is less costly to investors than VIVAX (0.17). DNLVX is a more actively managed with annual turnover of: 23.00 vs. VIVAX (10.00). VIVAX has a lower initial minimum investment than DNLVX: VIVAX (3000) vs DNLVX (100000). VIVAX annual gain was more profitable for investors over the last year : 7.07 vs. DNLVX (1.74). VIVAX return over 5 years is better than : 100.53 vs. DNLVX (82.14).
DNLVXVIVAXDNLVX / VIVAX
Total Expense Ratio1.040.17612%
Annual Report Gross Expense Ratio1.040.17612%
Fund Existence20 years32 years-
Gain YTD0.6241.84334%
Front LoadN/AN/A-
Min. Initial Investment10000030003,333%
Min. Initial Investment IRAN/AN/A-
Net Assets174M195B0%
Annual Yield % from dividends0.802.1437%
Returns for 1 year1.747.0725%
Returns for 3 years6.5616.4040%
Returns for 5 years82.14100.5382%
Returns for 10 years29.09107.1227%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FDMT3.280.29
+9.70%
4D Molecular Therapeutics
APLS23.000.32
+1.41%
Apellis Pharmaceuticals
BG78.010.16
+0.21%
Bunge Global SA
AMBC8.260.01
+0.12%
Ambac Financial Group
CNET1.46-0.02
-1.35%
ZW Data Action Technologies Inc